Management of Medications in Severe Renal Impairment

Introduction to Medication Management

• The American College of Cardiology and other guideline societies recommend that ACE inhibitors can be used in patients with GFR <30 mL/min/1.73 m² and are not nephrotoxic, though they should be discontinued if GFR falls below 10 mL/min/1.73 m²; metformin is absolutely contraindicated at GFR <30 mL/min/1.73 m² due to significant risk of lactic acidosis 1, 2, 3

ACE Inhibitors in Advanced CKD

• ACE inhibitors are safe and appropriate for use in severe renal impairment (GFR <30 mL/min/1.73 m²), providing cardiovascular and renal protection 4
• A 10-20% increase in serum creatinine after starting ACE inhibitors represents an expected and beneficial hemodynamic effect, not acute kidney injury 4
• The American Heart Association recommends monitoring GFR and serum potassium within 1 week of starting or escalating doses of ACE inhibitors 4
• Discontinue ACE inhibitors only if GFR declines by >30% or if hyperkalemia develops that cannot be managed 4
• Temporarily discontinue ACE inhibitors during serious intercurrent illness (sepsis, dehydration, hypotension) 4, 5

Metformin Contraindications

• The Endocrine Society recommends stopping metformin and not initiating metformin at GFR <30 mL/min/1.73 m² due to risk of metformin-associated lactic acidosis (MALA) 1, 3
• The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends a dosing algorithm by renal function: GFR ≥60, no dose adjustment needed; GFR 45-59, continue same dose; GFR 30-44, halve the dose; GFR <30, stop metformin completely 3

Safe Alternatives for Glycemic Control

• The American Diabetes Association recommends DPP-4 inhibitors, such as sitagliptin, saxagliptin, linagliptin, and alogliptin, as safe alternatives for glycemic control at GFR <30 mL/min/1.73 m² 1, 6
• GLP-1 receptor agonists, such as dulaglutide, liraglutide, and semaglutide, can be used at GFR <30 mL/min/1.73 m² and provide cardiovascular benefits 1, 3, 6
• Meglitinides, such as repaglinide and nateglinide, can be initiated conservatively at GFR <30 mL/min/1.73 m² 1, 6
• Insulin requirements decrease significantly in advanced CKD, and insulin is not nephrotoxic and can be safely used at any GFR level 1

Medications to Avoid

• The National Kidney Foundation recommends avoiding metformin, glyburide, NSAIDs, SGLT2 inhibitors, and exenatide in patients with GFR <30 mL/min/1.73 m² due to increased risk of lactic acidosis, hypoglycemia, acute kidney injury, or other adverse effects 1, 2, 5, 7, 6

Common Pitfalls to Avoid

• The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) recommends not relying solely on serum creatinine to assess renal function, as it may appear normal despite reduced GFR, especially in elderly or those with reduced muscle mass 5
• Temporarily discontinue potentially nephrotoxic medications during serious intercurrent illness, including ACE inhibitors, diuretics, NSAIDs, and metformin 4, 5
• Never combine NSAIDs with ACE inhibitors in patients with GFR <30, as this dramatically increases acute kidney injury risk 4, 7
• Monitor vitamin B12 levels in patients who were on metformin for more than 4 years before discontinuation 3
• Increase frequency of GFR monitoring to at least every 3-6 months when GFR <60 mL/min/1.73 m² 3, 5

Renally Contraindicated Cardiology Medications (eGFR < 30 mL/min/1.73 m²)

Absolute Contraindications – Anticoagulants

• Fondaparinux must not be used when creatinine clearance is < 30 mL/min; it is an absolute contraindication. 8, 9
• Rivaroxaban is contraindicated in patients with creatinine clearance < 30 mL/min. 8, 9
• Edoxaban is contraindicated when creatinine clearance falls below 30 mL/min. 8, 9

Absolute Contraindications – GLP‑1 Receptor Agonists

• Exenatide should not be prescribed when eGFR is < 30 mL/min/1.73 m². 10
• Lixisenatide should be avoided when eGFR is < 15 mL/min/1.73 m²; for eGFR 15‑29 mL/min only limited experience exists and close monitoring is required. 10

Absolute Contraindications – Antidiabetic Agents (Cardiovascular Comorbidity)

• Metformin is absolutely contraindicated at eGFR < 30 mL/min/1.73 m² because of a high risk of lactic acidosis. 11, 12, 10
• Glyburide (glibenclamide) must be avoided in any degree of renal impairment. 11, 12

Medications Requiring Dose Reduction (Not Contraindicated)

RAAS Antagonists

• ACE inhibitors, ARBs, and aldosterone antagonists remain nephroprotective at eGFR < 30 mL/min; they should not be routinely discontinued. 11, 12
• Initiate these agents at lower doses when eGFR < 45 mL/min and reassess renal function and serum potassium within 1 week of start. 11, 12

Beta‑Blockers

• Reduce beta‑blocker dose by ≈ 50 % when eGFR is < 30 mL/min/1.73 m². 11, 12

Digoxin

• Adjust digoxin dosing based on measured plasma concentrations as renal function declines; no outright contraindication. 11, 12

Low‑Molecular‑Weight Heparins (LMWH)

• Enoxaparin dose should be reduced to 1 mg/kg subcutaneously every 24 h (instead of every 12 h) when creatinine clearance is < 30 mL/min. 8
• For all LMWHs, halve the dose when eGFR < 30 mL/min, or consider switching to unfractionated heparin with anti‑factor Xa monitoring. 11, 12, 9

Warfarin

• In patients with eGFR < 30 mL/min, bleeding risk is increased; use lower warfarin doses and monitor INR closely. 11, 12

Medications to Avoid (Strong Recommendation Against Use)

NSAIDs

• NSAIDs should be avoided when eGFR < 30 mL/min/1.73 m² because they precipitate acute kidney injury and further renal decline. 11, 12

SGLT2 Inhibitors

• Canagliflozin must be discontinued when eGFR is persistently < 45 mL/min/1.73 m². 10
• Dapagliflozin is contraindicated at eGFR < 30 mL/min/1.73 m². 10
• Empagliflozin should be stopped when eGFR falls below 30 mL/min/1.73 m². 10

Critical Monitoring Requirements

• Prior to initiating any renally cleared cardiology medication, assess renal function and repeat assessments when clinical status suggests decline.
• After starting or escalating RAAS antagonists, monitor eGFR and serum potassium within 1 week. 11, 12
• During intercurrent illnesses (e.g., sepsis, dehydration, hypotension), temporarily suspend RAAS antagonists, diuretics, NSAIDs, and metformin to prevent acute kidney injury. 11, 12
• When LMWH is used in patients at high bleeding risk with eGFR < 30 mL/min, measure anti‑factor Xa levels to guide dosing. 9